Survodutide: separating the mechanism from the marketing
Purity across our Survodutide samples ranged from 98.2% to 99.4%. Here is the context.
ResearchDulaglutide
Also known as: LY2189265
Strong evidence
ClassGLP-1 receptor agonist (Fc fusion)
Research statusFDA-approved (branded forms)
CategoryGLP-1 / incretin
Independent tests1
Studies indexed2
Companies tested 1
Overview
A weekly GLP-1 agonist fused to an antibody fragment to extend its half-life, studied primarily for glycaemic control and cardiovascular risk.
Dulaglutide is classified as a glp-1 receptor agonist (fc fusion). Its current development status is: fda-approved (branded forms). Multiple randomised controlled trials in humans support the primary claims made for this compound.
The Peptide Institute tracks Dulaglutide because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.
Independent Testing
Independently tested companies that sell Dulaglutide
Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.
- Companies
- 1
- Samples
- 1
- Updated
- Jan 14, 2025
- 1 Northwind Telehealth Excellent Institute
Top Rated Dulaglutide97.3% average purity across 1 sample
Purity & Testing 81 Transparency 90 Samples 1 84 View company
Research & Studies
Studies library-
Immunogenicity and stability profile of Dulaglutide
Adds to the Dulaglutide evidence base without resolving the central question of human efficacy.
-
Dulaglutide in preclinical models: efficacy and translational limits
Characterises Dulaglutide activity in a controlled setting. Endpoints are surrogate measures rather than clinical outcomes.
Independent Testing
Testing databaseLaboratory verification of Dulaglutide products across the companies we index.
Dulaglutide Northwind Telehealth
Purity 97.3% Verified
Latest Coverage
New Cagrilintide data: reading the results critically
7 independently tested samples across 4 companies, and what the results say about Cagrilintide.
Study Summary
Regulators signal closer attention to Cagrilintide supply channels
A close reading of the Cagrilintide evidence, without the marketing layer.
RegulationCommunity Discussions
Forum 113 replies
77 replies
The Peptide Institute Weekly
Research. Testing. Regulation. No hype.
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
- New research, summarized in plain English
- Independent lab results as they publish
- Score and ranking movements